Inventor · disambiguated record
Alistair Ian Longshaw
Also filed as: LONGSHAW ALISTAIR IAN
20 granted patents·1 pending application·140 citations·filing 2010–2023
94Inventor score
Top patents by PatentIndex Score
21 records- 0197US9624196B2Inhibitor of p38 MAP kinaseRESPIVERT LTD·Filed 2016·Granted Apr 18, 2017·15 cites·5 claims
- 0297US9108950B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2012·Granted Aug 18, 2015·38 cites·13 claims
- 0396US9447076B2Inhibitor of p38 map kinaseRESPIVERT LTD·Filed 2015·Granted Sep 20, 2016·16 cites·18 claims
- 0492US10738032B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitorsRESPIVERT LTD·Filed 2019·Granted Aug 11, 2020·3 cites·24 claims
- 0592US9475796B21-pyrazolyl-3-((4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2012·Granted Oct 25, 2016·12 cites·14 claims
- 0692US9249125B2Pyrazole derivatives as p38 MAP inhibitorsRESPIVERT LTD·Filed 2013·Granted Feb 2, 2016·30 cites·12 claims
- 0791US10266519B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitorsRESPIVERT LTD·Filed 2017·Granted Apr 23, 2019·6 cites·11 claims
- 0889US9724347B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitorsRESPIVERT LTD·Filed 2016·Granted Aug 8, 2017·5 cites·17 claims
- 0988US9850231B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitorsRESPIVERT LTD·Filed 2015·Granted Dec 26, 2017·5 cites·8 claims
- 1086US10238658B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2018·Granted Mar 26, 2019·3 cites·19 claims
- 1183US10294216B2Pyrazolyl ureas as kinase inhibitorsRESPIVERT LTD·Filed 2017·Granted May 21, 2019·1 cites·13 claims
- 1283US9993478B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitorsRESPIVERT LTD·Filed 2017·Granted Jun 12, 2018·2 cites·19 claims
- 1380US2024343711A11-pyrazolyl-3- (4- ((2 -anilinopyrimidin- 4 - yl) oxy) napththalen- i - yl) ureas as p38 mapkinase inhibitorsRESPIVERT LTD·Filed 2023·Application pending·0 cites
- 1476US11634406B2Inhibitor of p38 MAP kinaseRESPIVERT LTD·Filed 2020·Granted Apr 25, 2023·0 cites·10 claims
- 1576US11142515B2Pyrazolyl-ureas as kinase inhibitorsRESPIVERT LTD·Filed 2019·Granted Oct 12, 2021·0 cites·9 claims
- 1676US9884845B2Pyrazolyl-ureas as kinase inhibitorsRESPIVERT LTD·Filed 2015·Granted Feb 6, 2018·1 cites·17 claims
- 1776US9493465B23-hydroxypyrrolidine inhibitors of 5′-methylthioadenosine phosphorylase and nucleosidaseEVANS GARY BRIAN·Filed 2010·Granted Nov 15, 2016·3 cites·15 claims
- 1870US10815217B2Inhibitor of p38 MAP kinaseRESPIVERT LTD·Filed 2018·Granted Oct 27, 2020·0 cites·13 claims
- 1969US10813932B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitorsRESPIVERT LTD·Filed 2019·Granted Oct 27, 2020·0 cites·18 claims
- 2068US10045980B2Inhibitor of p38 map kinaseRESPIVERT LTD·Filed 2017·Granted Aug 14, 2018·0 cites·13 claims
- 2153US9957272B23-hydroxypyrrolidine inhibitors of 5′-methylthioadenosine phosphorylase and nucleosidaseVICTORIA LINK LTD·Filed 2016·Granted May 1, 2018·0 cites·8 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →